Selected publications below:

Advancements in melanoma cancer metastasis models.
Nascentes Melo LM, Kumar S, Riess V, Szylo KJ, Eisenburger R, Schadendorf D, Ubellacker JM, Tasdogan A. Pigment Cell Melanoma Res (2023). PMID: 36478190

In vivo isotope tracing reveals a requirement for the electron transport chain in glucose and glutamine metabolism by tumors.
Pachnis P, Wu Z, Faubert B, Tasdogan A, Gu W, Shelton S, Solmonson A, Rao AD, Kaushik AK, Rogers TJ, Ubellacker JM, LaVigne CA, Yang C, Ko B, Ramesh V, Sudderth J, Zacharias LG, Martin-Sandoval MS, Do D, Mathews TP, Zhao Z, Mishra P, Morrison SJ, DeBerardinis RJ. Sci Adv (2022). PMID: 36044570

Emerging metabolomic tools to study cancer metastasis. Nascentes Melo L.M., Lesner N.P., Sabatier M., Ubellacker J.M.*, Tasdogan A.*. Trends in Cancer (2022). PMID: 35909026.

Lymph protects metastasizing melanoma cells from ferroptosis.
Ubellacker J.M., Tasdogan A., Ramesh V., Shen B., Mitchell E.C., Martin M.S., Gu Z., McCormick M.L., Durham A.B., Spitz D.R., Zhao Z., Mathews T.P., Morrison S.J. Nature. 585:113-118 (2020). PMID: 32814895.

Metabolic heterogeneity confers differences in melanoma metastatic potential.
Tasdogan A., Faubert B., Ramesh V., Ubellacker J.M., Shen B., Solmonson A., Murphy M.M., Gu Z., Gu W., Martin M., Kasitinon S.Y., Vandergriff T., Mathews T.P., Zhao Z., Schadendorf D., DeBerardinis R.J., Morrison S.J. Nature. 577(7788):115-120 (2019). PMID: 31853067.

A mechanosensitive peri-arteriolar niche for osteogenesis and lymphogenesis.
Shen B., Tasdogan A., Ubellacker J.M., Zhang J., Du L., Murphy M., Hu S., Yi Y., Kara N., Liu X., Guela S., Jia Y., Ramesh V., Embree C., Mitchell E.C., Hu Z., Zhao Z., Crane G.M., Morrison S.J. Nature. 591:438-444 (2020). PMID: 33627868.

Metabolomic profiling of rare cell populations isolated by flow cytometry from tissues.
DeVilbiss A.W., Zhao Z., Martin-Sandoval M.S., Ubellacker J.M., Tasdogan A., Agathocleous M., Mathews T.P., Morrison S.J. eLife. Jan 20 10.7554/eLife.61980. (2021). PMID: 33470192 

The unresolved role of systemic factors in bone metastasis.
Ubellacker J.M., McAllister S.S. J Bone Oncol. 5(3):96-99. (2016) Invited review. PMID: 27761365.

Zoledronic alters hematopoiesis and generates breast tumor-suppressive bone marrow cells.
Ubellacker, J.M., Haider, M.T., DeCristo, M.J., Brown, N.J., Silver, D.P., Holen, I., McAllister, SS. Breast Cancer Research. 19(1), 23 (2017). PMID: 28264701.

CDK4/6 inhibition triggers anti-tumour immunity.
Goel, S. & DeCristo, M.J., Watt, A.C., BrinJones, H., Sceneay, J., Li, B., Ubellacker, J.M., Xie, S., Ramm, S., Kim, HJ., Krop, I.E., Winer, E.P., Roberts, T.M., McAllister, S.S., Zhao, J.J. Nature. 548(7668), 417-475 (2017). PMID: 28813415.

Modulating bone marrow hematopoietic lineage potential to prevent bone metastasis in breast cancer.
Ubellacker JM, Baryawno N, Severe N, DeCristo MJ, Sceneay J, Hutchinson JN, Haider MT, Rhee CS, Qin Y, Gregory WM, Garrido-Castro AC, Holen I, Brown JE, Coleman RE, Scadden DT, McAllister SS. Cancer Res. Sep 15;78(18):5300-5314 (2018). PMID: 30065048.

For a full list of publications, visit Google Scholar.

The Ubellacker Lab is grateful for the following sources of funding that make our work possible.